These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 30287200)

  • 1. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
    Leleu X; Martin TG; Einsele H; Lyons RM; Durie BGM; Iskander KS; Ailawadhi S
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):9-22. PubMed ID: 30287200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The power of proteasome inhibition in multiple myeloma.
    Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
    Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.
    Ma H; Su Z; Sun F; Zhao N
    Acta Oncol; 2018 Feb; 57(2):290-296. PubMed ID: 28828905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
    Le Ray E; Jagannath S; Palumbo A
    Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
    Orlowski RZ
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2(12 0 2):56-64. PubMed ID: 25188482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.
    Steinmetz TH; Singh M; Lebioda A; Fink L; Schoehl M; Rieth A; Gonzalez-McQuire S; Engelhardt M
    J Med Econ; 2021; 24(1):114-122. PubMed ID: 33390079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
    Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
    Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
    Vandross A
    Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of multiple myeloma in the relapsed/refractory patient].
    Tabayashi T
    Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Old and new generation proteasome inhibitors in multiple myeloma.
    Montefusco V; Mussetti A; Salas MQ; Martinelli G; Cerchione C
    Panminerva Med; 2020 Dec; 62(4):193-206. PubMed ID: 32957744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.